menu
    • menu
    [{"orgOrder":0,"company":"PMG Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHILE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PG201","moa":"Immune","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PMG Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PMG Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PMG Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PMG Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHILE","productType":"Microorganism","year":"2013","type":"Inapplicable","leadProduct":"Layla","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"PMG Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PMG Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PMG Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PMG Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHILE","productType":"Microorganism","year":"2014","type":"Inapplicable","leadProduct":"Layla","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"PMG Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PMG Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PMG Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PMG Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHILE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PK101","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PMG Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PMG Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PMG Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PMG Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHILE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PK101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"PMG Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PMG Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PMG Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PMG Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHILE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PK101-002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"PMG Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PMG Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PMG Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by PMG Pharma

    Menu

    PMG Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PK101

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis

                            Details : PK101 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 26, 2021

                            Lead Product(s) : PK101

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PK101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

                            Details : PK101 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 15, 2019

                            Lead Product(s) : PK101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PK101-002

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-Drug Interaction Between PK101-001 and PK101-002

                            Details : PK101-002 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 12, 2018

                            Lead Product(s) : PK101-002

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Layla

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee

                            Details : Layla is a Microorganism drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            January 30, 2014

                            Lead Product(s) : Layla

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Layla

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients

                            Details : Layla is a Microorganism drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            January 15, 2013

                            Lead Product(s) : Layla

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PMG Pharma

                            Chile arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PG201

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in O...

                            Details : PG201 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 12, 2012

                            Lead Product(s) : PG201

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth